Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells.
Rigoni M, Riganti C, Vitale C, Griggio V, Campia I, Robino M, Foglietta M, Castella B, Sciancalepore P, Buondonno I, Drandi D, Ladetto M, Boccadoro M, Massaia M, Coscia M.
Rigoni M, et al. Among authors: campia i.
Oncotarget. 2015 Oct 6;6(30):29833-46. doi: 10.18632/oncotarget.4006.
Oncotarget. 2015.
PMID: 26284584
Free PMC article.